Matches in SemOpenAlex for { <https://semopenalex.org/work/W2272926813> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2272926813 abstract "6023 Background: The addition of trastuzumab (H) to a standard adjuvant therapy regimen (doxorubicin, cyclophosphamide, and paclitaxel; AC→T) is associated with a 52% reduction in risk (p < 0.0001) of disease recurrence in patients with HER2 positive operable breast cancer (Romond et al, NEJM 2005). A cost-effectiveness analysis was performed to assess the lifetime clinical and economic implications of this important clinical finding. Methods: A Markov model with three health states (disease-free survival [DFS], recurrence, and death) was used to estimate the likely cost-effectiveness (CE) for a 50 yr old woman. Efficacy results from both trials (NCCTG N9831/NSABP B-31) were used through 4 years, and projections of time to recurrence and death were based on the literature (EBCTCG, Lancet 2005). After 4 years, annual transition probabilities to recurrence and death are assumed to be the same in both arms. Cardiotoxicity was higher with H (Perez EA, ASCO 2005). Actual total dose of H was used which was lower than scheduled dose. Incremental costs associated with addition of H to adjuvant therapy were estimated using average wholesale prices, Medicare reimbursement rates and other published data. These costs included testing for HER2 status, drug and administration costs for H, cardiac monitoring, treatment of cardiotoxicity, treatment following recurrence, and end-of-life costs for dying patients. Utility estimates were derived from the literature. Results: Over a lifetime, the cost per quality-adjusted life year gained (QALY; discount rate 3%) is $27,800, with a range of $17,900 to $39,100 under multi-way sensitivity analysis. Projected life expectancy from the Markov model is 3 years longer for H patients (19.4 v 16.4 yrs). Over a 20-year horizon, addition of H to AC→T is estimated to cost an additional $46,300 on average, with an expected gain of 1.28 QALYs-a cost/QALY of $36,100. The key drivers of CE are the cost of treatment and the improvement in DFS. Conclusion: The model projects a cost-utility ratio that is below that of many treatments used for oncology patients. The use of trastuzumab in the adjuvant setting for HER2+ breast cancer is projected to be cost-effective. [Table: see text]" @default.
- W2272926813 created "2016-06-24" @default.
- W2272926813 creator A5043109470 @default.
- W2272926813 creator A5044492888 @default.
- W2272926813 creator A5065306642 @default.
- W2272926813 creator A5067342672 @default.
- W2272926813 creator A5072015843 @default.
- W2272926813 creator A5072323793 @default.
- W2272926813 date "2006-06-20" @default.
- W2272926813 modified "2023-09-26" @default.
- W2272926813 title "Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+ breast cancer" @default.
- W2272926813 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.6023" @default.
- W2272926813 hasPublicationYear "2006" @default.
- W2272926813 type Work @default.
- W2272926813 sameAs 2272926813 @default.
- W2272926813 citedByCount "5" @default.
- W2272926813 countsByYear W22729268132012 @default.
- W2272926813 crossrefType "journal-article" @default.
- W2272926813 hasAuthorship W2272926813A5043109470 @default.
- W2272926813 hasAuthorship W2272926813A5044492888 @default.
- W2272926813 hasAuthorship W2272926813A5065306642 @default.
- W2272926813 hasAuthorship W2272926813A5067342672 @default.
- W2272926813 hasAuthorship W2272926813A5072015843 @default.
- W2272926813 hasAuthorship W2272926813A5072323793 @default.
- W2272926813 hasConcept C112930515 @default.
- W2272926813 hasConcept C121608353 @default.
- W2272926813 hasConcept C126322002 @default.
- W2272926813 hasConcept C141071460 @default.
- W2272926813 hasConcept C143998085 @default.
- W2272926813 hasConcept C160735492 @default.
- W2272926813 hasConcept C162324750 @default.
- W2272926813 hasConcept C2776694085 @default.
- W2272926813 hasConcept C2777863537 @default.
- W2272926813 hasConcept C2778233292 @default.
- W2272926813 hasConcept C2779703844 @default.
- W2272926813 hasConcept C2779786085 @default.
- W2272926813 hasConcept C2781413609 @default.
- W2272926813 hasConcept C3019080777 @default.
- W2272926813 hasConcept C50522688 @default.
- W2272926813 hasConcept C515549039 @default.
- W2272926813 hasConcept C530470458 @default.
- W2272926813 hasConcept C535046627 @default.
- W2272926813 hasConcept C64332521 @default.
- W2272926813 hasConcept C71924100 @default.
- W2272926813 hasConceptScore W2272926813C112930515 @default.
- W2272926813 hasConceptScore W2272926813C121608353 @default.
- W2272926813 hasConceptScore W2272926813C126322002 @default.
- W2272926813 hasConceptScore W2272926813C141071460 @default.
- W2272926813 hasConceptScore W2272926813C143998085 @default.
- W2272926813 hasConceptScore W2272926813C160735492 @default.
- W2272926813 hasConceptScore W2272926813C162324750 @default.
- W2272926813 hasConceptScore W2272926813C2776694085 @default.
- W2272926813 hasConceptScore W2272926813C2777863537 @default.
- W2272926813 hasConceptScore W2272926813C2778233292 @default.
- W2272926813 hasConceptScore W2272926813C2779703844 @default.
- W2272926813 hasConceptScore W2272926813C2779786085 @default.
- W2272926813 hasConceptScore W2272926813C2781413609 @default.
- W2272926813 hasConceptScore W2272926813C3019080777 @default.
- W2272926813 hasConceptScore W2272926813C50522688 @default.
- W2272926813 hasConceptScore W2272926813C515549039 @default.
- W2272926813 hasConceptScore W2272926813C530470458 @default.
- W2272926813 hasConceptScore W2272926813C535046627 @default.
- W2272926813 hasConceptScore W2272926813C64332521 @default.
- W2272926813 hasConceptScore W2272926813C71924100 @default.
- W2272926813 hasLocation W22729268131 @default.
- W2272926813 hasOpenAccess W2272926813 @default.
- W2272926813 hasPrimaryLocation W22729268131 @default.
- W2272926813 hasRelatedWork W2095950656 @default.
- W2272926813 hasRelatedWork W2248113534 @default.
- W2272926813 hasRelatedWork W2420535504 @default.
- W2272926813 hasRelatedWork W2506569264 @default.
- W2272926813 hasRelatedWork W2955324663 @default.
- W2272926813 hasRelatedWork W3157815744 @default.
- W2272926813 hasRelatedWork W4205367416 @default.
- W2272926813 hasRelatedWork W4225390758 @default.
- W2272926813 hasRelatedWork W2342209702 @default.
- W2272926813 hasRelatedWork W2589698823 @default.
- W2272926813 isParatext "false" @default.
- W2272926813 isRetracted "false" @default.
- W2272926813 magId "2272926813" @default.
- W2272926813 workType "article" @default.